POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology · 2026-10 · 101 (10) · 2632-2651
DOI: 10.1002/ajh.70438 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 07.07.2026. Verfasst von Angela Dispenzieri. Beteiligte Einrichtung: Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: POEMS Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hematologic Malignancies Fund, NIH HHS, Predolin Foundation.
Abstract (Originalsprache)
Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnosis The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. Risk Stratification Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR. Risk‐Adapted Therapy For those patients with a dominant plasmacytoma, first line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement should receive systemic therapy. Corticosteroids are temporizing, but alkylators and lenalidomide are the mainstays of treatment, the former either in the form of low dose conventional therapy or as high‐dose conditioning for stem cell transplantation. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Daratumumab combinations also appear promising based on case series. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Angela Dispenzieri
Förderung
- Hematologic Malignancies Fund
- NIH HHS
- Predolin Foundation
- NCI NIH HHS
- Andrew & Lillian A. Posey Foundation
- National Institutes of Health
Zitieren
APA
Dispenzieri, A. (2026). POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management. American Journal of Hematology, 101(10), 2632-2651. https://doi.org/10.1002/ajh.70438
Vancouver
Dispenzieri A. POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management. American Journal of Hematology. 2026;101(10):2632-2651. doi:10.1002/ajh.70438
BibTeX
@article{Dispenzieri2026,
author = {Dispenzieri, Angela},
title = {POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {10},
pages = {2632--2651},
doi = {10.1002/ajh.70438}
}
EUVIMED